Rapport Therapeutics, Inc.Rapport Therapeutics, Inc.Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc.

No trades

Fundamentals and stats

Operating, investing, and financing activities

Free cash flow for Q3 25 is -17.6 M USD. For 2024, it was -67.23 M USD and operating cash flow was -64.83 M USD.

Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
Q2 '25
Q3 '25
TTM
Free cash flowYoY growth